An Open-Label, Extension, Phase II Study to Evaluate the Long-Term Safety and Efficacy of MRA [tocilizumab] in Patients With RA Who Were Participated in Study MRA009JP.
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2013
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 23 Jun 2009 Planned end date changed from 1 Dec 2009 to 1 Jul 2009 as reported by ClinicalTrials.gov.
- 30 Jan 2009 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov, last updated 30 Jan 2009
- 18 Dec 2005 New trial record.